Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0A3JJ
|
|||
| Former ID |
DIB013876
|
|||
| Drug Name |
Pentacea
|
|||
| Synonyms |
HMN14-734; Bispecific CEA antibody (radiotherapeutic pretargeting), IBC; Anti-CEA/anti-In-DTPA antibody, IBC
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Small-cell lung cancer [ICD-11: 2C25.Y; ICD-9: 162.9] | Phase 2 | [1] | |
| Company |
IBC Pharmaceuticals Inc
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Carcinoembryonic antigen CEA (CD66e) | Target Info | . | [2] |
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013510) | |||
| REF 2 | Antibody fragments: Hope and hype. MAbs. 2010 Jan-Feb; 2(1): 77-83. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.